Pharma Journalist -

Forbius, a clinical-stage company that develops novel biologics for the treatment of fibrosis and cancer, announced that the first patient has been dosed in a Phase 1b trial assessing…
Read More...

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet…
Read More...

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), and Adagene Inc., an antibody…
Read More...

The 7th Annual PREDiCT: Tumor Models Boston summit will be held on July 16 – 18 2019 in Boston, MA. For its anticipated return, Tumor Models Boston rebrands alongside its sister events…
Read More...

Velabs Therapeutics announced that it has entered into an agreement with Chiome Bioscience, Inc., Tokyo, to jointly discover modulatory and functional antibodies for one of Chiome’s…
Read More...

Fulcrum Therapeutics announced an exclusive worldwide license agreement with GlaxoSmithKline (GSK) for development and commercialization of the investigational drug losmapimod. Fulcrum…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for the treatment of moderate to severe…
Read More...

Teva Pharmaceutical Industries Ltd. provided an update that the Company is discontinuing the clinical development program for use of fremanezumab in cluster headaches. A pre-specified…
Read More...

FSD Pharma Inc. and Prismic Pharmaceuticals Inc. announced that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD…
Read More...

UroGen Pharma Ltd. announced that it has entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a…
Read More...